Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adicet Bio, Inc. (ACET : NSDQ)

• Company Description    Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif. Number of Employees: 152

• Price / Volume Information    Yesterday's Closing Price: $0.61 Daily Weekly Monthly 20 Day Moving Average: 359,192 shares Shares Outstanding: 82.71 (millions) Market Capitalization: $50.21 (millions) Beta: 1.62 52 Week High: $1.70 52 Week Low: $0.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.85% -23.41% 12 Week 13.03% -3.45% Year To Date -36.90% -40.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 131 DARTMOUTH STREET 3RD FLOOR - BOSTON,MA 02116 USA ph: 650-503-9095 fax: - abowdidge@adicetbio.com http://www.adicetbio.com

• General Corporate Information    Officers Chen Schor - President; Chief Executive Officer and Director Nick Harvey - Chief Financial Officer Jeffrey Chodakewitz - Director Steve Dubin - Director Carl L. Gordon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 007002108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 82.71 Most Recent Split Date: 9.00 (0.14:1) Beta: 1.62 Market Capitalization: $50.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.13 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.31 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 11.43% vs. Previous Quarter: 3.12% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -59.05 12/31/24 - -52.52 ROA 06/30/25 - - 03/31/25 - -50.66 12/31/24 - -45.57 Current Ratio 06/30/25 - - 03/31/25 - 9.34 12/31/24 - 9.29 Quick Ratio 06/30/25 - - 03/31/25 - 9.34 12/31/24 - 9.29 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 1.95 12/31/24 - 2.26 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©